Loading...
Frontpage2024-11-08T14:40:53+01:00

The aim of the EuroSpA Research Collaboration Network

The aim of the EuroSpA Research Collaboration Network (RCN) is to jointly address research questions in SpA including, but not limited to, real world effectiveness and safety profiles of biologic therapies. This is done by retrospectively and prospectively collecting real life patient data from European registers.

The collaboration promotes opportunities to identify unmet needs in the treatment of SpA patients by utilizing high-quality data from existing patient registries.

Our aims are in line with the EMA initiative for patient registries and are consistent with discussions at the EMA workshop “How to make better use of patient registries to collect high-quality data on medicines” held in London on October 28th, 2016 in London.

EuroSpA RCN Scope

Currently the collaboration consists of 17 registries (see map).

There is a recognized openness to include other interested registries and to other parties such as health authorities (EMA and local regulatory bodies) and patient organizations, although the extent of their involvement will need to be further defined.

Acknowledgements

Novartis Pharma AG for supporting the EuroSpA collaboration.
UCB Biopharma SRL for supporting the EuroSpA collaboration.

Registries that contribute data to the collaboration

ARC (Netherlands)

ATTRA (Czech Republic)

BIOBADASER (Spain)

Biorx.si (Slovenia)

BSRBR-AS/BSR-PsA (United Kingdom)

DANBIO (Denmark)

ERSBTR (Estonia)

GISEA (Italy)

ICEBIO (Iceland)

NOR-DMARD (Norway)

RABBIT-SpA (Germany)

Reuma.pt (Portugal)

ROBFIN (Finland)

RRBR (Romania)

SCQM (Switzerland)

SRQ (Sweden)

TURKBIO (Turkey)

The most recent EuroSpA publications

EuroSpA publication 4.3

By |August 20th, 2024|Categories: News|

Comparing DAPSA, DAPSA28, and DAS28-CRP in PatientsWith Psoriatic Arthritis Initiating a First Tumor NecrosisFactor Inhibitor Across Nine European Countries Click here to [...]

Comments Off on EuroSpA publication 4.3

EuroSpA publication A1.2

By |August 13th, 2024|Categories: News|

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study Click here to access full article [...]

Comments Off on EuroSpA publication A1.2

EuroSpA publication D6.1

By |August 13th, 2024|Categories: News|

Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors [...]

Comments Off on EuroSpA publication D6.1

EuroSpA publication D8.1

By |July 8th, 2024|Categories: News|

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte [...]

Comments Off on EuroSpA publication D8.1

EuroSpA publication D3.1

By |May 27th, 2024|Categories: News|

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response [...]

Comments Off on EuroSpA publication D3.1

To see full list, please click Publications in top menu

EuroSpA Research Collaboration Network explained by chairpersons Professor Merete Lund Hetland and Professor Mikkel Østergaard
Why is it meaningful to be a part of EuroSpA? – an interview with 8 members of the Scientific Committee

EuroSpA meetings

EuroSpA Scientific Committee consists of representatives from the 17 participating registries, who meets for hybrid meetings twice yearly in Copenhagen and online.

Go to Top